|Table of Contents|

Evaluation of serum MUC5AC in combination with CA199 for the diagnosis of pancreatic cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
852-855
Research Field:
Publishing date:

Info

Title:
Evaluation of serum MUC5AC in combination with CA199 for the diagnosis of pancreatic cancer
Author(s):
LI Xiangsu; WANG Dongdong; WU Xudong
Department of Gastroenterology,the First People's Hospital of Yancheng City,Jiangsu Yancheng 224005,China.
Keywords:
biomarker; carbohydrate antigen 199(CA199); mucin 5AC(MUC5AC); pancreatic cancer(PC)
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2022.05.020
Abstract:
Objective:To evaluate the performance of serum MUC5AC in combination with carbohydrate antigen 199(CA199) for the diagnosis of PC.Methods:This was a hospital-based single-central case-control study.Thirty-eight patients with PC,38 pancreatic benign controls and 38 healthy controls were recruited from our hospital,based on 1∶1 age-/gender-match.Serum levels of MUC5AC were evaluated by commercial ELISA kits.CA199 was measured by chemiluminescence immunoassay.The cutoff value of MUC5AC was determined based on Youden index.Results:Serum MUC5AC in patients with PC［157.1(97.9~357.1) ng/mL］ presented higher levels than those in healthy controls［60.8(44.7~91.2) ng/mL,P＜0.001］ and pancreatic benign controls［93.8(57.0~117.6) ng/mL,P＜0.001).MUC5AC showed a fine performance［AUC 0.824,95%CI(0.745~0.904),sensitivity 0.737,specificity 0.776］ in identifying PC,however no different from CA199(P=0.406).The combined biomarkers panel presented better performance and improved specificity to differentiate PC from controls［AUC 0.916(0.866~0.966),sensitivity 0.842,specificity 0.842］ than CA199(P=0.045) or MUC5AC alone(P=0.001).Conclusion:Serum MUC5AC is a potential biomarker for PC.The combination with CA199 improved performance.

References:

[1] TEMPERO MA,MALAFA MP,AL-HAWARY M,et al.Pancreatic adenocarcinoma,version 2.2017,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2017,15:1028-1061.
[2] BALLEHANINNA UK,CHAMBERLAIN RS.The clinical utility of serum CA 19-9 in the diagnosis,prognosis and management of pancreatic adenocarcinoma:An evidence based appraisal［J］.J Gastrointest Oncol,2012,3:105-119.
[3] KAUR S,SMITH LM,PATEL A,et al.A Combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer:A multicenter study［J］.Am J Gastroenterol,2017,112:172-183.
[4] 中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南(2014)［J］.中华消化外科杂志,2014,13(11):831-837. Pancreatic Surgery Group of Surgery Branch of China.Guideline for the diagnosis and treatment of pancreatic adenocarcinoma(2014 edition)［J］.Chinese Journal of Digestive Surgery,2014,13(11):831-837.
[5] FARRELL JJ.Pancreatic cysts and guidelines［J］.Dig Dis Sci,2017,62:1827-1839.
[6] YOUNG MR,WAGNER PD,GHOSH S,et al.Validation of biomarkers for early detection of pancreatic cancer:Summary of the alliance of pancreatic cancer consortia for biomarkers for early detection workshop［J］.Pancreas,2018,47(2):135-141.
[7] ZHANG Q,CHEN S,ZENG L,et al.New developments in the early diagnosis of pancreatic cancer［J］.Expert Rev Gastroenterol Hepatol,2017，11(2):149-156.
[8] SIERZEGA M,MLYNARSKI D,TOMASZEWSKA R,et al.Semiquantitative immunohistochemistry for mucin(MUC1,MUC2,MUC3,MUC4,MUC5AC and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance［J］.Histopathology,2016,69:582-591.
[9] HOSHI H,SAWADA T,UCHIDA M,et al.Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer［J］.Int J Oncol,2011,38:619-627.
[10] IACOBUZIO-DONAHUE CA,ASHFAQ R,et al.Highly expressed genes in pancreatic ductal adenocarcinomas:a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies［J］.Cancer Res,2003,63:8614-8622.
[11] YAMAZOE S,TANAKA H,SAWADA T,et al.RNA interference suppression of mucin 5AC(MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells［J］.J Exp Clin Cancer Res,2010,29:53.
[12] HOSHI H,SAWADA T,UCHIDA M,et al.MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways［J］.Int J Oncol,2013,42:887-893.
[13] WIKTOROWICZ M,MLYNARSKI D,PACH R,et al.Rationale and feasibility of mucin expression profiling by qRT-PCR as diagnostic biomarkers in cytology specimens of pancreatic cancer［J］.Pancreatology,2018,18:977-982.

Memo

Memo:
江苏省盐城市医学科技发展计划项目（编号：YK2017024）
Last Update: 2022-01-27